Stay updated with breaking news from Nasdaq Enta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company’s stock, valued at approximately $1,253,000. Federated Hermes Inc. owned approximately 0.63% […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday. Separately, JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday. Separately, JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” […]
Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,064 shares of the biotechnology company’s stock, valued at approximately $57,000. Other institutional investors and hedge funds have […]
Virtus ETF Advisers LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 11.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,784 shares of the biotechnology company’s stock after selling 1,654 shares during the period. Virtus ETF Advisers LLC’s holdings in Enanta Pharmaceuticals were worth $143,000 […]